var data={"title":"Angiotensin converting enzyme inhibitors in acute myocardial infarction: Mechanisms of action","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Angiotensin converting enzyme inhibitors in acute myocardial infarction: Mechanisms of action</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/contributors\" class=\"contributor contributor_credentials\">Guy S Reeder, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/contributors\" class=\"contributor contributor_credentials\">Juan Carlos Kaski, DSc, MD, DM (Hons), FRCP, FESC, FACC, FAHA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/contributors\" class=\"contributor contributor_credentials\">Gordon M Saperia, MD, FACC</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;May 10, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of modalities may be beneficial in the management of the patient with acute myocardial infarction (MI), including direct angioplasty or fibrinolysis, <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>, angiotensin converting enzyme (ACE) inhibitors, beta blockers, and nitrates. (See <a href=\"topic.htm?path=overview-of-the-acute-management-of-st-elevation-myocardial-infarction\" class=\"medical medical_review\">&quot;Overview of the acute management of ST-elevation myocardial infarction&quot;</a> and <a href=\"topic.htm?path=overview-of-the-acute-management-of-non-st-elevation-acute-coronary-syndromes\" class=\"medical medical_review\">&quot;Overview of the acute management of non-ST elevation acute coronary syndromes&quot;</a>.)</p><p>A meta-analysis concluded that administration of an ACE inhibitor within 3 to 16 days of infarction can slow the progression of cardiovascular disease and improve the survival rate (<a href=\"image.htm?imageKey=CARD%2F58405\" class=\"graphic graphic_figure graphicRef58405 \">figure 1</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/1\" class=\"abstract_t\">1</a>]. The mechanisms by which ACE inhibitors improve survival after MI will be reviewed here, beginning with a discussion of infarct expansion. The clinical data supporting the use of ACE inhibitors in this setting are presented elsewhere. (See <a href=\"topic.htm?path=angiotensin-converting-enzyme-inhibitors-and-receptor-blockers-in-acute-myocardial-infarction-clinical-trials\" class=\"medical medical_review\">&quot;Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">INFARCT EXPANSION AND REMODELING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Survivors of acute myocardial infarction (MI) have a significant risk of future cardiovascular events. Infarct expansion, due to thinning and stretching of the infarct zone, occurs within hours to days of a transmural MI and is an important prognostic determinant. Significant left ventricular dilation can begin within three hours from the onset of a first myocardial infarction, particularly among patients with anterior wall damage [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/2\" class=\"abstract_t\">2</a>]. Patients who develop infarct expansion have a high risk of developing heart failure and sudden death. Pathologic evidence of infarct expansion has been found in up to 60 percent of patients dying from complications of an MI [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/3\" class=\"abstract_t\">3</a>].</p><p>Ventricular dilatation itself may be deleterious, independent of the reduction in overall myocardial contractility induced by the infarct. Consistent with this hypothesis is the observation in an animal study that preventing left ventricular dilatation with a restraining mesh placed over the anticipated area of infarction preserved left ventricular geometry and function [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/4\" class=\"abstract_t\">4</a>].</p><p>Following the initial insult in the area of infarction, <strong>ventricular remodeling</strong> can lead to progressive regional myocardial dysfunction [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/5-8\" class=\"abstract_t\">5-8</a>]. The remodeling process begins with myocyte necrosis and the formation of fibrotic scar; it is followed by elongation of the infarcted segment and then dilatation and hypertrophy of the border zone ventricular myocardium (<a href=\"image.htm?imageKey=CARD%2F69944\" class=\"graphic graphic_figure graphicRef69944 \">figure 2</a>). The extent of microvascular obstruction within the infarcted area during the early healing phase after an infarction is indicative of absent blood flow and predicts left ventricular remodeling and dilatation, independent of infarct size [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/9\" class=\"abstract_t\">9</a>]. There is no increase in interstitial fibrosis in the noninfarcted tissue remote from the scar [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/10\" class=\"abstract_t\">10</a>]; this tissue retains normal contractility even though it is involved in the remodeling process. (See <a href=\"topic.htm?path=cardiac-remodeling-clinical-assessment-and-therapy\" class=\"medical medical_review\">&quot;Cardiac remodeling: Clinical assessment and therapy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">MECHANISM OF ACTION OF ACE INHIBITION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Attenuation of remodeling is thought to play an important role in the survival benefit associated with angiotensin converting enzyme (ACE) inhibitors after myocardial infarction. These drugs also may have favorable effects on ischemic preconditioning, recurrent myocardial infarction and ischemia, sudden death, and fibrinolysis (reduction in plasma plasminogen activator inhibitor-1). (See <a href=\"#H6\" class=\"local\">'Reduction in recurrent myocardial infarction and ischemia'</a> below.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Attenuation of remodeling</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the early stages, ventricular dilatation can be considered beneficial, maintaining stroke volume through the Frank-Starling mechanism. However, over time, the dilating ventricle causes detrimental effects by exerting further demands on the surviving myocardium, a result of increases in wall tension (<a href=\"image.htm?imageKey=CARD%2F58408\" class=\"graphic graphic_figure graphicRef58408 \">figure 3</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/11\" class=\"abstract_t\">11</a>].</p><p>ACE inhibitors have favorable effects on certain parameters of remodeling, slowing the rate of left ventricular dilatation over time [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/12-15\" class=\"abstract_t\">12-15</a>]; the combination of an ACE inhibitor and an angiotensin II receptor blocker may be even more effective than an ACE inhibitor alone [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/16\" class=\"abstract_t\">16</a>]. (See <a href=\"topic.htm?path=angiotensin-converting-enzyme-inhibitors-and-receptor-blockers-in-acute-myocardial-infarction-clinical-trials\" class=\"medical medical_review\">&quot;Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials&quot;</a>.) This effect is presumably mediated by inhibition of angiotensin II, which appears to play an important role in the remodeling process. In support of this hypothesis are the observations in humans that ACE is markedly increased at the edge of the infarct scar [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/17\" class=\"abstract_t\">17</a>] and that the incidence of left ventricular (LV) dilatation after myocardial infarction (MI) is increased in patients with the ACE DD genotype (a genotype associated with increased ACE activity) [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/18\" class=\"abstract_t\">18</a>]. (See <a href=\"topic.htm?path=cardiac-remodeling-basic-aspects#H14\" class=\"medical medical_review\">&quot;Cardiac remodeling: Basic aspects&quot;, section on 'Role of angiotensin II'</a>.)</p><p>The effect of ACE inhibitors on infarct expansion reflects a chronic benefit. There is also experimental evidence that ACE inhibitors have more acute benefits, limiting the following changes that can occur during acute ischemia: myocardial injury, degradation of high-energy phosphate stores, and impairment of endothelium-dependent arteriolar responses [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/19,20\" class=\"abstract_t\">19,20</a>]. These observations constitute part of the rationale for the early administration of ACE inhibitors (within the first 24 hours) after the diagnosis of acute MI has been made [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/21\" class=\"abstract_t\">21</a>]. (See <a href=\"topic.htm?path=angiotensin-converting-enzyme-inhibitors-and-receptor-blockers-in-acute-myocardial-infarction-recommendations-for-use\" class=\"medical medical_review\">&quot;Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Effect on ischemic preconditioning</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Ventricular remodeling after a myocardial infarction may interfere with ischemic preconditioning. This was examined in one animal study that found that the myocardium that was remodeled after an infarction was refractory to ischemic preconditioning; this was due to the interruption of cellular signaling of mitochondrial ATP-dependent potassium channels [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/22\" class=\"abstract_t\">22</a>]. The angiotensin II receptor blocker <a href=\"topic.htm?path=valsartan-drug-information\" class=\"drug drug_general\">valsartan</a> was beneficial for suppressing remodeling and preserving ischemic preconditioning. (See <a href=\"topic.htm?path=myocardial-ischemic-conditioning-pathogenesis\" class=\"medical medical_review\">&quot;Myocardial ischemic conditioning: Pathogenesis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Reduction in recurrent myocardial infarction and ischemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>ACE inhibitors appear to reduce the incidence of recurrent myocardial infarction. As an example, the Survival and Ventricular Enlargement (SAVE) Trial of 2231 patients found that <a href=\"topic.htm?path=captopril-drug-information\" class=\"drug drug_general\">captopril</a> was associated with a significant reduction in recurrent MI by 25 percent. This benefit was noted in all patient groups, including those who received other adjunctive therapies such as fibrinolysis, <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>, <span class=\"nowrap\">and/or</span> beta blockers [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/23\" class=\"abstract_t\">23</a>].</p><p>The reduction in recurrent MI suggests that ACE inhibitor therapy has benefits beyond afterload reduction. How this might occur is not known; ACE inhibitors do not appear to reduce the degree of atherosclerosis [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/24\" class=\"abstract_t\">24</a>]. The following factors may contribute:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Improvement in the oxygen <span class=\"nowrap\">supply/demand</span> ratio of the myocardium by reversing angiotensin II-induced vasoconstriction and inotropic activity. Among the clinical benefits that could be explained by this mechanism are increased myocardial blood flow to ischemic regions [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/25\" class=\"abstract_t\">25</a>] and an improvement in resting left ventricular function and reduced diastolic dysfunction during exercise [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/26\" class=\"abstract_t\">26</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Improvement in endothelial function [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/27\" class=\"abstract_t\">27</a>]. This is probably related to inhibition of angiotensin II-related vasoconstriction and to diminished breakdown of bradykinin, which enhances endothelial release of nitric oxide&nbsp;[<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/28\" class=\"abstract_t\">28</a>]. (See <a href=\"topic.htm?path=coronary-artery-endothelial-dysfunction-clinical-aspects\" class=\"medical medical_review\">&quot;Coronary artery endothelial dysfunction: Clinical aspects&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Improvement in the hypercoagulable state after an MI by reducing plasma plasminogen activator inhibitor-1 (PAI-1) [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/29-31\" class=\"abstract_t\">29-31</a>] and tissue factor levels [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/32\" class=\"abstract_t\">32</a>] and increasing the release of tissue type plasminogen activator (tPA) by the endothelial cells within the coronary artery. Bradykinin stimulates the release of tPA, an effect that is enhanced by an ACE inhibitor, at least in women [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/33,34\" class=\"abstract_t\">33,34</a>]. (See <a href=\"topic.htm?path=fibrinolytic-markers-and-cardiovascular-risk\" class=\"medical medical_review\">&quot;Fibrinolytic markers and cardiovascular risk&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Inhibition of the activation and accumulation of macrophages and monocytes by diminishing the levels of monocyte chemoattractant protein-1 [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/32\" class=\"abstract_t\">32</a>].</p><p/><p>There are conflicting data regarding a possible benefit of ACE inhibitor therapy in reducing exercise-induced ischemia. In one trial of 43 patients randomly assigned to either <a href=\"topic.htm?path=enalapril-drug-information\" class=\"drug drug_general\">enalapril</a> 10 mg twice daily or placebo, the exercise time to 1 mm ST segment depression was significantly increased by enalapril at 12 weeks, though not at three weeks [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/35\" class=\"abstract_t\">35</a>]. In another trial of 336 patients randomly assigned to either <a href=\"topic.htm?path=quinapril-drug-information\" class=\"drug drug_general\">quinapril</a> 40 mg daily or placebo, there was no improvement in the exercise time to 1 mm ST segment depression at eight weeks [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/36\" class=\"abstract_t\">36</a>]. The placebo group was then crossed over to 80 mg quinapril daily while the 40 mg group continued the same dose; again there was no difference eight weeks later.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Reduction in sudden death</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>ACE inhibitors reduce overall cardiovascular and sudden-death mortality [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/37\" class=\"abstract_t\">37</a>]. There are several mechanisms that might contribute to the reduction in sudden death (see <a href=\"topic.htm?path=pathophysiology-and-etiology-of-sudden-cardiac-arrest\" class=\"medical medical_review\">&quot;Pathophysiology and etiology of sudden cardiac arrest&quot;</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Decrease in sympathetic activity along with an improvement in baroreceptor sensitivity which enhances vagal tone [<a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/38\" class=\"abstract_t\">38</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Attenuation of ventricular remodeling and ventricular dilation, which are factors for arrhythmogenesis</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Decrease in the incidence of recurrent myocardial infarction, which increases electrical instability</p><p/><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">SUMMARY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The addition of angiotensin converting enzyme (ACE) inhibitor or receptor blocker to standard medical therapy (including <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>, thienopyridine, beta blocker, and statin) in patients with recent myocardial infarction improves cardiovascular outcomes. (See <a href=\"topic.htm?path=angiotensin-converting-enzyme-inhibitors-and-receptor-blockers-in-acute-myocardial-infarction-recommendations-for-use\" class=\"medical medical_review\">&quot;Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use&quot;</a> and <a href=\"topic.htm?path=overview-of-the-non-acute-management-of-st-elevation-myocardial-infarction\" class=\"medical medical_review\">&quot;Overview of the non-acute management of ST elevation myocardial infarction&quot;</a> and <a href=\"topic.htm?path=overview-of-the-non-acute-management-of-unstable-angina-and-non-st-elevation-myocardial-infarction\" class=\"medical medical_review\">&quot;Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction&quot;</a>.)</p><p>Attenuation of remodeling is thought to play a critically important role in the survival benefit associated with ACE inhibitors after myocardial infarction. (See <a href=\"#H4\" class=\"local\">'Attenuation of remodeling'</a> above.)</p><p>Other possible mechanisms of benefits include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Preservation of ischemic preconditioning (see <a href=\"#H5\" class=\"local\">'Effect on ischemic preconditioning'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reduction in recurrent myocardial infarction and ischemia (see <a href=\"#H6\" class=\"local\">'Reduction in recurrent myocardial infarction and ischemia'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reduction in sudden death (see <a href=\"#H7\" class=\"local\">'Reduction in sudden death'</a> above)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/1\" class=\"nounderline abstract_t\">Flather MD, Yusuf S, K&oslash;ber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355:1575.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/2\" class=\"nounderline abstract_t\">Korup E, Dalsgaard D, Nyvad O, et al. Comparison of degrees of left ventricular dilation within three hours and up to six days after onset of first acute myocardial infarction. Am J Cardiol 1997; 80:449.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/3\" class=\"nounderline abstract_t\">Hutchins GM, Bulkley BH. Infarct expansion versus extension: two different complications of acute myocardial infarction. Am J Cardiol 1978; 41:1127.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/4\" class=\"nounderline abstract_t\">Kelley ST, Malekan R, Gorman JH 3rd, et al. Restraining infarct expansion preserves left ventricular geometry and function after acute anteroapical infarction. Circulation 1999; 99:135.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/5\" class=\"nounderline abstract_t\">Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation 1993; 87:755.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/6\" class=\"nounderline abstract_t\">Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990; 81:1161.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/7\" class=\"nounderline abstract_t\">Pfeffer MA, Pfeffer JM, Lamas GA. Development and prevention of congestive heart failure following myocardial infarction. Circulation 1993; 87:IV120.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/8\" class=\"nounderline abstract_t\">Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000; 101:2981.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/9\" class=\"nounderline abstract_t\">Gerber BL, Rochitte CE, Melin JA, et al. Microvascular obstruction and left ventricular remodeling early after acute myocardial infarction. Circulation 2000; 101:2734.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/10\" class=\"nounderline abstract_t\">Marijianowski MM, Teeling P, Becker AE. Remodeling after myocardial infarction in humans is not associated with interstitial fibrosis of noninfarcted myocardium. J Am Coll Cardiol 1997; 30:76.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/11\" class=\"nounderline abstract_t\">Yousef ZR, Redwood SR, Marber MS. Postinfarction left ventricular remodelling: where are the theories and trials leading us? Heart 2000; 83:76.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/12\" class=\"nounderline abstract_t\">Konstam MA, Kronenberg MW, Rousseau MF, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation 1993; 88:2277.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/13\" class=\"nounderline abstract_t\">Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 1995; 91:2573.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/14\" class=\"nounderline abstract_t\">Pfeffer MA, Lamas GA, Vaughan DE, et al. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988; 319:80.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/15\" class=\"nounderline abstract_t\">Pfeffer MA, Greaves SC, Arnold JM, et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation 1997; 95:2643.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/16\" class=\"nounderline abstract_t\">Mankad S, d'Amato TA, Reichek N, et al. Combined angiotensin II receptor antagonism and angiotensin-converting enzyme inhibition further attenuates postinfarction left ventricular remodeling. Circulation 2001; 103:2845.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/17\" class=\"nounderline abstract_t\">Hokimoto S, Yasue H, Fujimoto K, et al. Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction. Circulation 1996; 94:1513.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/18\" class=\"nounderline abstract_t\">Oosterga M, Voors AA, de Kam PJ, et al. Plasma angiotensin-converting enzyme activity and left ventricular dilation after myocardial infarction. Circulation 1997; 95:2607.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/19\" class=\"nounderline abstract_t\">Li K, Chen X. Protective effects of captopril and enalapril on myocardial ischemia and reperfusion damage of rat. J Mol Cell Cardiol 1987; 19:909.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/20\" class=\"nounderline abstract_t\">Piana RN, Wang SY, Friedman M, Sellke FW. Angiotensin-converting enzyme inhibition preserves endothelium-dependent coronary microvascular responses during short-term ischemia-reperfusion. Circulation 1996; 93:544.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/21\" class=\"nounderline abstract_t\">Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998; 97:2202.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/22\" class=\"nounderline abstract_t\">Miki T, Miura T, Tsuchida A, et al. Cardioprotective mechanism of ischemic preconditioning is impaired by postinfarct ventricular remodeling through angiotensin II type 1 receptor activation. Circulation 2000; 102:458.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/23\" class=\"nounderline abstract_t\">Vantrimpont P, Rouleau JL, Wun CC, et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol 1997; 29:229.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/24\" class=\"nounderline abstract_t\">MacMahon S, Sharpe N, Gamble G, et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol 2000; 36:438.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/25\" class=\"nounderline abstract_t\">Schneider CA, Voth E, Moka D, et al. Improvement of myocardial blood flow to ischemic regions by angiotensin-converting enzyme inhibition with quinaprilat IV: a study using [15O] water dobutamine stress positron emission tomography. J Am Coll Cardiol 1999; 34:1005.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/26\" class=\"nounderline abstract_t\">Willenheimer R, Rydberg E, Oberg L, et al. ACE inhibition with ramipril improves left ventricular function at rest and post exercise in patients with stable ischaemic heart disease and preserved left ventricular systolic function. Eur Heart J 1999; 20:1647.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/27\" class=\"nounderline abstract_t\">Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94:258.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/28\" class=\"nounderline abstract_t\">Prasad A, Husain S, Quyyumi AA. Effect of enalaprilat on nitric oxide activity in coronary artery disease. Am J Cardiol 1999; 84:1.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/29\" class=\"nounderline abstract_t\">Vaughan DE, Rouleau JL, Ridker PM, et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 1997; 96:442.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/30\" class=\"nounderline abstract_t\">Brown NJ, Abbas A, Byrne D, et al. Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women. Circulation 2002; 105:304.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/31\" class=\"nounderline abstract_t\">Ridker PM, Gaboury CL, Conlin PR, et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87:1969.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/32\" class=\"nounderline abstract_t\">Soejima H, Ogawa H, Yasue H, et al. Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. J Am Coll Cardiol 1999; 34:983.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/33\" class=\"nounderline abstract_t\">Minai K, Matsumoto T, Horie H, et al. Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2001; 37:1565.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/34\" class=\"nounderline abstract_t\">Pretorius M, Rosenbaum D, Vaughan DE, Brown NJ. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation 2003; 107:579.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/35\" class=\"nounderline abstract_t\">van den Heuvel AF, Dunselman PH, Kingma T, et al. Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade. J Am Coll Cardiol 2001; 37:470.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/36\" class=\"nounderline abstract_t\">Pepine CJ, Rouleau JL, Annis K, et al. Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial. J Am Coll Cardiol 2003; 42:2049.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/37\" class=\"nounderline abstract_t\">Domanski MJ, Exner DV, Borkowf CB, et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999; 33:598.</a></li><li><a href=\"https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-in-acute-myocardial-infarction-mechanisms-of-action/abstract/38\" class=\"nounderline abstract_t\">Hikosaka M, Yuasa F, Yuyama R, et al. Effect of angiotensin-converting enzyme inhibitor on cardiopulmonary baroreflex sensitivity in patients with acute myocardial infarction. Am J Cardiol 2000; 86:1241.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 87 Version 8.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H8\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">INFARCT EXPANSION AND REMODELING</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">MECHANISM OF ACTION OF ACE INHIBITION</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Attenuation of remodeling</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Effect on ischemic preconditioning</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Reduction in recurrent myocardial infarction and ischemia</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Reduction in sudden death</a></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"CARD/87|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/58405\" class=\"graphic graphic_figure\">- ACE inhibitors improve outcome after MI</a></li><li><a href=\"image.htm?imageKey=CARD/69944\" class=\"graphic graphic_figure\">- Cardiac remodeling after anterior MI</a></li><li><a href=\"image.htm?imageKey=CARD/58408\" class=\"graphic graphic_figure\">- The law of Laplace</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=angiotensin-converting-enzyme-inhibitors-and-receptor-blockers-in-acute-myocardial-infarction-clinical-trials\" class=\"medical medical_review\">Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=angiotensin-converting-enzyme-inhibitors-and-receptor-blockers-in-acute-myocardial-infarction-recommendations-for-use\" class=\"medical medical_review\">Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cardiac-remodeling-basic-aspects\" class=\"medical medical_review\">Cardiac remodeling: Basic aspects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cardiac-remodeling-clinical-assessment-and-therapy\" class=\"medical medical_review\">Cardiac remodeling: Clinical assessment and therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=coronary-artery-endothelial-dysfunction-clinical-aspects\" class=\"medical medical_review\">Coronary artery endothelial dysfunction: Clinical aspects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fibrinolytic-markers-and-cardiovascular-risk\" class=\"medical medical_review\">Fibrinolytic markers and cardiovascular risk</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=myocardial-ischemic-conditioning-pathogenesis\" class=\"medical medical_review\">Myocardial ischemic conditioning: Pathogenesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-acute-management-of-st-elevation-myocardial-infarction\" class=\"medical medical_review\">Overview of the acute management of ST-elevation myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-acute-management-of-non-st-elevation-acute-coronary-syndromes\" class=\"medical medical_review\">Overview of the acute management of non-ST elevation acute coronary syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-non-acute-management-of-st-elevation-myocardial-infarction\" class=\"medical medical_review\">Overview of the non-acute management of ST elevation myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-non-acute-management-of-unstable-angina-and-non-st-elevation-myocardial-infarction\" class=\"medical medical_review\">Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathophysiology-and-etiology-of-sudden-cardiac-arrest\" class=\"medical medical_review\">Pathophysiology and etiology of sudden cardiac arrest</a></li></ul></div></div>","javascript":null}